Vicuron (NASDAQ:MICU)
Historical Stock Chart
From Jul 2019 to Jul 2024
Vicuron Pharmaceuticals Promotes David S. Krause, M.D., to
Executive Vice President and Chief Medical Officer
KING OF PRUSSIA, Penn., Jan. 24 /PRNewswire-FirstCall/ -- Vicuron
Pharmaceuticals Inc. (Nasdaq: MICU; Nuovo Mercato) announced today that it has
promoted David S. Krause, M.D. to the position of Executive Vice President and
Chief Medical Officer. He will replace Timothy J. Henkel, M.D., Ph.D., who is
leaving the company to pursue other opportunities.
"David has played a pivotal role in developing our two lead product candidates,
dalbavancin and anidulafungin," said George F. Horner, III, Vicuron's President
and Chief Executive Officer. "His leadership strength and proven track record
will serve us well as we move through the final phase of clinical coordination
in the regulatory process necessary to bring these two products to market."
Since joining Vicuron in 2002, Dr. Krause has been serving as Senior Vice
President of Clinical Research and Medical Affairs and, in that role, has been
largely responsible for the execution of all of the company's clinical trial
programs to date. Prior to joining Vicuron, he worked for more than a decade
in various clinical and medical affairs positions at GlaxoSmithKline (GSK)
focused mostly on the company's pediatric and adult vaccine programs. During
his tenure, Dr. Krause played an integral role in successfully bringing a
number of infectious disease products to the market, including Engerix-B(R),
Havrix(R), Twinrix(R) and Infanrix(R), all of which became leading products for
the prevention of hepatitis B, A, and childhood pertussis.
Dr. Krause received his M.D. degree from Temple University School of Medicine
and his B.A. degree from The Pennsylvania State University. He completed his
residency in internal medicine at Temple University Hospital in 1980, and is a
Fellow of the American College of Physicians. Prior to joining industry at
SmithKline Beecham in 1990, Dr. Krause practiced internal medicine for 10 years
in the Philadelphia area. He also served as Adjunct Assistant Professor of
Medicine at Temple University Hospital from 1990 - 2000 and Clinical Assistant
Professor of Medicine at the Medical College of Pennsylvania from 1992 - 1994.
His work has been published and presented in numerous infectious disease
journals and at scientific conferences worldwide.
About Vicuron Pharmaceuticals
Vicuron Pharmaceuticals is a biopharmaceutical company focused on discovering,
developing, manufacturing and commercializing vital medicine for seriously ill
patients. The company has two New Drug Applications pending with the U.S. Food
and Drug Administration for its lead products, dalbavancin, a novel intravenous
antibiotic for the treatment of serious Gram-positive infections, and
anidulafungin, a novel antifungal agent. Vicuron's versatile research engine
integrates industry-leading expertise in functional genomics, natural products
discovery, mechanism-based drug design and combinatorial and medicinal
chemistry. These approaches are yielding promising novel and next-generation
compounds, many of which are in the later stages of preclinical development. In
addition, the company has research and development collaborations with leading
pharmaceutical companies, such as Novartis and Pfizer.
Forward-Looking Statements
This news release contains forward-looking statements that predict or describe
future events or trends. The matters described in these forward- looking
statements are subject to known and unknown risks, uncertainties and other
unpredictable factors, many of which are beyond Vicuron's control. Vicuron
faces many risks that could cause its actual performance to differ materially
from the results predicted by its forward-looking statements, including the
possibilities that clinical trials and the results thereof might be delayed or
unsuccessful, that the timing of the filing of any new drug application or any
amendment to a new drug application might be delayed, that clinical trials
might indicate that a product candidate is unsafe or ineffective, that the FDA
might require additional information to be submitted and additional actions to
be taken before it will make any decision, that any filed new drug application
may not be approved by the FDA, that ongoing proprietary and collaborative
research might not occur or yield useful results, that the pipeline may not
yield a new clinical candidate or a commercial product, that a third party may
not be willing to license Vicuron's product candidates on terms acceptable to
it or at all, that competitors might develop superior substitutes for Vicuron's
products or market these competitive products more effectively, that a sales
force may not be developed as contemplated and that one or more of Vicuron's
product candidates may not be commercialized successfully. The reports that
Vicuron files with the U.S. Securities and Exchange Commission contain a fuller
description of these and many other risks to which Vicuron is subject. Because
of those risks, Vicuron's actual results, performance or achievements may
differ materially from the results, performance or achievements contemplated by
its forward-looking statement. The information set forth in this news release
represents management's current expectations and intentions. Vicuron assumes no
responsibility to issue updates to the forward-looking matters discussed in
this news release.
DATASOURCE: Vicuron Pharmaceuticals Inc.
CONTACT: Dov A. Goldstein, M.D. of Vicuron Pharmaceuticals Inc.,
+1-610-205-2312, or ; or E. Blair Schoeb of WeissComm
Partners, +1-212-923-6737, or ; or Aline Schimmel
of Burns McClellan, +1-212-213-0006, or , both for
Vicuron Pharmaceuticals Inc.
Web site: http://www.vicuron.com/